



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 13, 2022

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai -400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Submission of half yearly disclosure on Related Party Transactions
Ref: Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the disclosure of Related Party Transactions for the half year ended March 31, 2022.

Kindly acknowledge receipt of the same.

Thanking you

Yours faithfully
For NATCO Pharma Limited


Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Encl. As Above.

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED MARCH 31, 2022
(In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

(Amount in INR Million)


Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee*	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance as on 01/10/2021	Closing balance as on 31/03/2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
1	Natco Pharma Ltd		Time Cap Overseas Limited, Mauritius		Subsidiary Company	Investment in Equity Shares	279.70	279.70									Business Development	
2	Natco Pharma Ltd		Natco Pharma (Canada) Inc. Canada		Subsidiary Company	Sale of Products	217.53	217.53	8.97	-14.91								
3	Natco Pharma Ltd		Natco Pharma Asia Pte Ltd, Singapore		Subsidiary Company	Interest income on Loan	1.44	1.44										
						Repayment of Loan given	114.49	114.49	114.49									
						Interest receivable			13.16									
						Interest Received	14.60	14.60										
						Sale of Products	55.38	55.38	9.59	47.85								
4	Natco Pharma Ltd		Natcofarma Do Brasil Ltda., Brazil		Stedp down Subsidiary Company	Purchases	0.21	0.21										
						Sale of Products	176.37	176.37	212.34	169								
						Corporate Guarantee Given	-	-	293.98	299								
						Financial Gurantee Liability	-	-		8								
5	Natco Pharma Ltd		Natco Pharma Australia Pty Ltd., Australia		Subsidiary Company	Investment in Equity Shares	-	-										
6	Natco Pharma Ltd		Natco Pharma Inc., United States of America		Subsidiary Company	Investment in Equity Shares	1,142.27	1,142.27								Acquisition of Dash Pharmaceuticals LLC		
7	Natco Pharma Ltd		Natco Lifesciences Philippines Inc., Philippines		Subsidiary Company	Investment in Equity Shares	5.24	5.24										
						Sale of Products	0.49	0.49	3.57	3.27								
						Interest income on Loan	0.11	0.11		0.11								
						Loan given	-	-	4.51	4.59								
8	Natco Pharma Ltd		Time Cap Pharma Labs Limited		Entities in which Directors have control or have	Rental Exepense	3.30	3.30	0.97									
9	Natco Pharma Ltd		Natco Trust		Entities in which Directors have control or have significant influence	Donations	2.74	2.74										
						Rentsl Income	0.06	0.06										
						Contribution to CSR Activities	73.61	73.61										



S. No	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee*	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance as on 01/10/2021	Closing balance as on 31/03/2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/unsecured
10	Natco Pharma Ltd		V C Nannapaneni		Key Management Personnel	Managerial Remuneration	9.75	9.75	0.76	0.85							
						Leave encashment	0.94	0.94									
						Rental Exepense	1.50	1.50									
11	Natco Pharma Ltd		Rajeev Nannapaneni		Key Management Personnel	Managerial Remuneration	9.00	9.00	0.76	1.26							
						Leave encashment	0.86	0.86									
						Rental Exepense	1.50	1.50									
12	Natco Pharma Ltd		Potluri Prasad Sivaramakrishna		Key Management Personnel	Managerial Remuneration	12.22	12.22	0.71	0.64							
						Leave encashment	0.52	0.52									
						Interest received	0.16	0.16									
						Repayment of Loan given	2.05	2.05	2.28	0.39							
13	Natco Pharma Ltd		Lingarao Donthineni		Key Management Personnel	Managerial Remuneration	22.17	22.17	0.71	0.65							
						Leave encashment	0.52	0.52									
						Interest Income on Loan	2.39	2.39									
						Repayment of Loan given	7.89	7.89	34.07	28.57							
14	Natco Pharma Ltd		S V V N Appa Rao		Chief Financial Officer	Managerial remuneration	4.07	4.07	0.25	0.18							
						Leave encashment	0.24	0.24									
15	Natco Pharma Ltd		Adinarayana M		Company Secretary	Managerial remuneration	2.81	2.81	0.10	-							
						Leave encashment	0.18	0.18									
16	Natco Pharma Ltd		Govinda Prasad Dasu		Independent Director	Sitting fee	0.30	0.30									
17	Natco Pharma Ltd		Leela Digumarti		Independent Director	Sitting fee	0.28	0.28									
18	Natco Pharma Ltd		Umamaheshwararao naidu Madireddi		Independent Director	Sitting fee	0.36	0.36									
19	Natco Pharma Ltd		Sreerama Muerthy Gubbala		Independent Director	Sitting fee	0.44	0.44									
20	Natco Pharma Ltd		Venkateswara Rao Thallapaka		Independent Director	Sitting fee	0.32	0.32									

Note: 1. *As per the provisions of the Companies Act, 2013 and/or approval of the Audit Committee or Board of Directors or shareholders as applicable
2. The PAN details are not to be included in the disclosure pursuant to guidance note issued by the stock exchanges.
3. Amounts have been rounded off to nearest million in financial statements whereas in the above statement, the company provided values in two digits.



SVVN Appa Rao
SVVN Appa Rao
Chief Finacila Officer